KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Fulgent Genetics (FLGT) over the last 10 years, with Q3 2025 value amounting to $86.2 million.

  • Fulgent Genetics' Total Non-Current Liabilities fell 92.02% to $86.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.2 million, marking a year-over-year decrease of 92.02%. This contributed to the annual value of $83.8 million for FY2024, which is 359.48% down from last year.
  • As of Q3 2025, Fulgent Genetics' Total Non-Current Liabilities stood at $86.2 million, which was down 92.02% from $82.3 million recorded in Q2 2025.
  • Fulgent Genetics' 5-year Total Non-Current Liabilities high stood at $197.0 million for Q1 2021, and its period low was $74.7 million during Q2 2023.
  • Its 5-year average for Total Non-Current Liabilities is $104.6 million, with a median of $89.3 million in 2024.
  • Per our database at Business Quant, Fulgent Genetics' Total Non-Current Liabilities skyrocketed by 15620.59% in 2021 and then tumbled by 4224.3% in 2023.
  • Fulgent Genetics' Total Non-Current Liabilities (Quarter) stood at $106.0 million in 2021, then dropped by 7.63% to $97.9 million in 2022, then decreased by 11.22% to $87.0 million in 2023, then decreased by 3.59% to $83.8 million in 2024, then increased by 2.88% to $86.2 million in 2025.
  • Its last three reported values are $86.2 million in Q3 2025, $82.3 million for Q2 2025, and $76.9 million during Q1 2025.